Cavalier Investments’s Corcept Therapeutics CORT Stock Holding History

Cavalier Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-76,000	Closed	-$1.19M	–	162
2018 Q2	$1.19M	Hold	76,000	–	–	0.4%	53
2018 Q1	$1.25M	Hold	76,000	–	–	0.44%	45
2017 Q4	$1.37M	Buy	76,000 +51,000	+204%	+$924K	0.55%	42
2017 Q3	$483K	Buy	+25,000	New	+$373K	0.23%	81

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cavalier Investments's CORT Position: Q3 2018 in Review

Cavalier Investments sold out of Corcept Therapeutics (CORT) in Q3 2018, closing a stake of 76,000 shares — an estimated $1.19M sold.

Cavalier Investments first reported a position in CORT in Q3 2017 and held it in 4 quarters. The position peaked at $1.37M in Q4 2017. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

Cavalier Investments reported no remaining Corcept Therapeutics position as of Q3 2018 after selling out during the quarter.
Cavalier Investments sold 76,000 Corcept Therapeutics shares in Q3 2018, an estimated $1.19M.
Cavalier Investments first reported a position in Corcept Therapeutics in Q3 2017 and held it in 4 quarters.
Cavalier Investments's Corcept Therapeutics position peaked at $1.37M in Q4 2017.
207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Cavalier Investments's 13F filing for Q3 2018, filed 13 Nov 2018.